As clinical evidence mounts demonstrating the power of combining oncolytic viruses and checkpoint inhibitors, companies are scrambling to get in on the action.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity
Nature Communications Open Access 31 August 2021
-
Oncolytic virus-derived type I interferon restricts CAR T cell therapy
Nature Communications Open Access 24 June 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ribas, A. et al. Cell 170, 1109–1119.e10 (2017).
Mullard, A. Nat. Rev. Drug Discov. 17, 86 (2018).
Emens, L.A. et al. Eur. J. Cancer 81, 116–129 (2017).
Ngwa, W. et al. Nat. Rev. Cancer 18, 313–322 (2018).
Garcia-Carbonero, R. et al. J. Immunother. Cancer 5, 71 (2017).
Fueyo, J. et al. Oncogene 19, 2–12 (2000).
Fueyo, J. et al. J. Natl. Cancer Inst. 95, 652–660 (2003).
Sampath, P. et al. Mol. Ther. 21, 620–628 (2013).
Gujar, S., Pol, J.G., Kim, Y., Lee, P.W. & Kroemer, G. Trends Immunol. 39, 209–221 (2018).
Pourchet, A. et al. EBioMedicine 5, 59–67 (2016)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Senior, M. Checkpoint inhibitors go viral. Nat Biotechnol 37, 12–17 (2019). https://doi.org/10.1038/nbt.4327
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.4327
This article is cited by
-
A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity
Nature Communications (2021)
-
Oncolytic virus-derived type I interferon restricts CAR T cell therapy
Nature Communications (2020)
-
Optimizing oncolytic virotherapy in cancer treatment
Nature Reviews Drug Discovery (2019)
